On May 18, 2021, National Resilience announced that the Government of Canada will invest CAD 199.2 million ($163.8 million), through the Strategic Innovation Fund, in the company’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and expand production capacity.

This project will help increase manufacturing capacity for vaccines and therapeutics, including novel technologies such as mRNA that are now being used to fight COVID-19. The expansion will build on RBI’s existing strengths as an important biomanufacturing organization in Canada, maintaining 295 existing jobs and create 205 new full-time positions at the Mississauga facility.

RBI, located in Mississauga, is a 136,000 sq ft (12,800 m²) biomanufacturing facility that currently provides process and analytical development, scale up, drug substance and drug product / fill finish manufacturing for a variety of medicines.